Company news
Luye Pharma Group Ltd. news in 2024
Luye Pharma Group Ltd.'s news releases, calls and decks from 2024, newest first.
Class 1 Innovative Antidepressant Targeting NET/DAT/GABAAR Approved for Clinical Trials in China
November 11, 2024
Luye Pharma Announces 2024 Half Year Results
August 29, 2024
Luye Pharma mRNA-based Therapeutic HPV Vaccine LY01620 Approved for Clinical Trials in China
August 13, 2024
Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in China
August 5, 2024
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating...
July 28, 2024
Luye Pharma Will Receive RMB 1.6 Billion Strategic Investment for Shenzhen Luye
July 23, 2024
Analgesic Drug Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) Approved for...
July 4, 2024
Manufacturing Facility for Paliperidone Palmitate Extended-release Injectable Suspension (LY03010) Passes FDA’s PAI...
June 27, 2024
Jinyouping (Rotigotine Microspheres for Injection) Approved for Marketing in China
June 19, 2024
Meibirui (Paliperidone Palmitate Injection) Approved for Marketing in China for Treating Schizophrenia
June 10, 2024